MX2017003546A - Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih. - Google Patents

Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih.

Info

Publication number
MX2017003546A
MX2017003546A MX2017003546A MX2017003546A MX2017003546A MX 2017003546 A MX2017003546 A MX 2017003546A MX 2017003546 A MX2017003546 A MX 2017003546A MX 2017003546 A MX2017003546 A MX 2017003546A MX 2017003546 A MX2017003546 A MX 2017003546A
Authority
MX
Mexico
Prior art keywords
hiv
treatment
monoclonal antibodies
healing
media
Prior art date
Application number
MX2017003546A
Other languages
English (en)
Spanish (es)
Inventor
Yi Wang Chang
Original Assignee
Ubi Ip Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubi Ip Holdings filed Critical Ubi Ip Holdings
Publication of MX2017003546A publication Critical patent/MX2017003546A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017003546A 2014-09-16 2014-11-11 Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih. MX2017003546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051200P 2014-09-16 2014-09-16
PCT/US2014/065048 WO2016043788A1 (en) 2014-09-16 2014-11-11 Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition

Publications (1)

Publication Number Publication Date
MX2017003546A true MX2017003546A (es) 2017-08-14

Family

ID=55533661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003546A MX2017003546A (es) 2014-09-16 2014-11-11 Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih.

Country Status (14)

Country Link
US (1) US11180555B2 (enExample)
EP (1) EP3194442A4 (enExample)
JP (2) JP6716544B2 (enExample)
KR (1) KR20170054478A (enExample)
CN (1) CN107074944B (enExample)
AU (2) AU2014406462A1 (enExample)
BR (1) BR112017005134A2 (enExample)
CA (1) CA2961464A1 (enExample)
MX (1) MX2017003546A (enExample)
RU (1) RU2762315C2 (enExample)
SG (1) SG11201702056YA (enExample)
TW (1) TWI695720B (enExample)
WO (1) WO2016043788A1 (enExample)
ZA (1) ZA201701856B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017003546A (es) * 2014-09-16 2017-08-14 Ubi Ip Holdings Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih.
SG10202100268RA (en) * 2016-08-13 2021-02-25 United Biopharma Inc Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients
SG11202007815TA (en) * 2018-03-05 2020-09-29 Oncoimmune Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
WO2021146272A1 (en) * 2020-01-13 2021-07-22 The Regents Of The University Of California Methods for treating viral infections
CN116063506A (zh) * 2022-09-02 2023-05-05 华道(上海)生物医药有限公司 一种分离的抗体及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381295A (en) 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
DE3828582A1 (de) 1988-08-23 1990-03-01 Max Planck Gesellschaft Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren
EP0365209A3 (en) 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
JPH0725794B2 (ja) 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
ATE153536T1 (de) 1990-11-27 1997-06-15 Biogen Inc Hiv-induzierte synzytien blockierender anti-cd-4- antikörper
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JPH06125783A (ja) 1991-12-28 1994-05-10 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ抗体およびその調製方法
DE69535002T2 (de) 1994-03-08 2006-12-07 Memorial Sloan-Kettering Cancer Center Rekombinante humanisierte antikörper gegen fb5
US5961976A (en) 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US5962319A (en) 1997-05-19 1999-10-05 Bml, Inc. Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene
JP3231262B2 (ja) 1996-06-05 2001-11-19 株式会社ビー・エム・エル ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体
JPH10155489A (ja) 1996-11-27 1998-06-16 Asahi Chem Ind Co Ltd 組換え抗体及びそれをコードする核酸
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
WO1999061629A1 (fr) 1998-05-25 1999-12-02 Asahi Kasei Kogyo Kabushiki Kaisha Dispositif pour la separation cellulaire et procede de separation
US6090388A (en) 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
CA2299893A1 (en) * 1999-03-02 2000-09-02 Carlos O. Stalgis Hiv therapy
CA2469901C (en) 2001-12-11 2017-07-04 Biotectid Gmbh Use of a labelled ligand having specificity for the human cd4 molecule to produce a diagnostic agent for analysing migration and/or distribution patterns of cell populations
JP2003327536A (ja) 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
US20030211470A1 (en) 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
US7501494B2 (en) * 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
KR100633856B1 (ko) * 2005-07-08 2006-10-13 조통래 산소와 오존을 함유한 미세기포가 녹아 있는 작물의병해충방제제
WO2007094983A2 (en) * 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
WO2008134046A1 (en) * 2007-04-27 2008-11-06 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
MX2017003546A (es) * 2014-09-16 2017-08-14 Ubi Ip Holdings Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih.

Also Published As

Publication number Publication date
RU2762315C2 (ru) 2021-12-17
RU2017112967A (ru) 2018-10-17
JP6716544B2 (ja) 2020-07-01
JP2017529355A (ja) 2017-10-05
TWI695720B (zh) 2020-06-11
ZA201701856B (en) 2020-08-26
CN107074944A (zh) 2017-08-18
JP2020097569A (ja) 2020-06-25
US20170369576A1 (en) 2017-12-28
CN107074944B (zh) 2025-12-05
TW201611845A (en) 2016-04-01
US11180555B2 (en) 2021-11-23
SG11201702056YA (en) 2017-04-27
EP3194442A4 (en) 2018-05-23
KR20170054478A (ko) 2017-05-17
CA2961464A1 (en) 2016-03-24
BR112017005134A2 (pt) 2017-12-12
RU2017112967A3 (enExample) 2018-10-17
AU2021203071A1 (en) 2021-06-17
AU2021203071B2 (en) 2024-11-21
WO2016043788A1 (en) 2016-03-24
AU2014406462A1 (en) 2017-04-06
EP3194442A1 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
BR112019006876A2 (pt) anticorpos e composições anti-lag-3
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
UY40486A (es) Anticuerpo anti-MASP-3, proceso para la producción del anticuerpo y composiciones
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
BR112016025470A2 (pt) ?hdl terapêutico?
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
MX2019001814A (es) Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
BR112019027387A8 (pt) Composições imunogênicas
BR112018013272A2 (pt) composições e métodos para detectar e tratar câncer esofágico
BR112017013093A2 (pt) processos para a preparação de um composto de diariltio-hidantoína
CL2017000152A1 (es) Derivados de isoindolinona
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
MX2017003546A (es) Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih.
BR112018013271A2 (pt) composições e métodos para detectar e tratar câncer de ovário
BR112018013268A2 (pt) composições e métodos para detectar e tratar câncer gástrico
BR112017025264A2 (pt) tratamento de prurido
UY36801A (es) PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCION DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICION QUE COMPRENDE IgM